Weekday Japan business intelligence for finance professionals.

Join the list
Tokyo Brief東 京 ブ リ ー フ

Japan's day, wrapped and delivered by morning.

Company2 articles
Companies

Astellas Pharma Inc.

Latest Tokyo Brief coverage on Astellas Pharma Inc., tracking filings, financial news, and market signals from Japan.

Code
4503
Exchange
TSE
Coverage
2 articles

Latest coverage

TSE:4503

  1. Astellas's Cancer Drugs and a Weak Yen Combine to Nearly Double Quarterly Profit

    A weaker yen added ¥60bn to Astellas Pharma's quarterly revenue and helped core operating profit jump 55.6% to ¥221.4bn, but strong sales of PADCEV and newer cancer drugs did the rest of the work, and the company is still not raising its full-year forecast.

  2. Astellas revenue passes ¥2.1tn as profit and ROE recover

    Revenue rose to ¥2,139,245,000,000 in the year to March 2026 from ¥1,912,323,000,000 a year earlier, while profit before tax jumped to ¥376,587,000,000 and net profit attributable to owners of parent to ¥291,535,000,000. ROE reached 17.4%, and a separate internal control report said financial-reporting controls were effective as of March 31.